Neuronetics’ NeuroStar TMS Gains TRICARE Coverage For Adolescents 15+, Expanding Access To Advanced Depression Therapy Nationwide

Neuronetics, Inc., the maker of NeuroStar® Advanced Therapy, announced that TriWest, the regional administrator for TRICARE, has updated its medical policy to include transcranial magnetic stimulation (TMS) coverage for adolescents aged 15 and older. This expansion marks an important milestone in improving access to advanced treatment options for young patients struggling with major depressive disorder (MDD). The updated policy, effective immediately, applies to TRICARE beneficiaries across 23 U.S. states, including California, Texas, Washington, and Illinois.

“TRICARE’s decision to expand coverage for TMS to adolescents is a significant step forward in ensuring that younger patients struggling with depression now have access to this life-changing treatment,” said Keith J. Sullivan, President and CEO of Neuronetics, Inc. “We applaud TRICARE and TriWest for recognizing the importance of providing innovative, evidence-based care to those who need it most, and we remain committed to working with providers and policymakers to expand adolescent access to TMS nationwide.”

TRICARE, which primarily serves active and retired U.S. military members and their families, will now provide coverage for NeuroStar TMS—a non-invasive, FDA-cleared treatment for depression that uses magnetic pulses to stimulate areas of the brain associated with mood regulation. Approximately 4.3 million adolescents aged 15–21 in the U.S. experience major depression, often facing limited medication options and challenges with treatment efficacy or side effects. NeuroStar TMS offers a safe, non-drug alternative that can be used as a first-line or add-on therapy, without requiring prior medication failures, and has demonstrated strong clinical outcomes in this age group.

"The demands of military life can create unique stressors for the children of service members, increasing their vulnerability to depression and other mental health challenges,” said Geoffrey Grammer, MD, Chief Medical Officer of Neuronetics and retired U.S. Army Colonel. “By expanding coverage to include NeuroStar TMS, TriWest is taking a meaningful step toward ensuring that the sons and daughters of our active-duty and retired military heroes receive the care and support that honors their families’ service to our nation."

Since receiving FDA clearance for adolescent patients in 2024, NeuroStar TMS has gained coverage from several major insurers, including Cigna’s Evernorth Health Services, BlueCross BlueShield HCSC, Humana, Aetna, Medi-Cal, and Pacific Source. Neuronetics continues to lead the TMS industry, not only as the first company with adolescent FDA clearance but also as the only TMS provider with a dedicated health policy team working directly with payors and providers to drive national coverage expansion and improve access to mental health care.